Communicated by Ulf Landegren
Nonoptical Massive Parallel DNA Sequencing of BRCA1 and BRCA2 Genes in a Diagnostic Setting
Article first published online: 11 FEB 2013
© 2013 Wiley Periodicals, Inc.
Volume 34, Issue 4, pages 629–635, April 2013
How to Cite
Costa, J. L., Sousa, S., Justino, A., Kay, T., Fernandes, S., Cirnes, L., Schmitt, F. and Machado, J. C. (2013), Nonoptical Massive Parallel DNA Sequencing of BRCA1 and BRCA2 Genes in a Diagnostic Setting. Hum. Mutat., 34: 629–635. doi: 10.1002/humu.22272
Contract grant sponsors: The study was funded by the research grants “Anti-EGFR Effective” and “PPS5 Consórcio Do IT” from the funding agency “ADI–Agencia de Inovação.” IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Education and Science and is partially supported by FCT, the Portuguese Foundation for Science and Technology.
- Issue published online: 20 MAR 2013
- Article first published online: 11 FEB 2013
- Accepted manuscript online: 11 JAN 2013 07:50AM EST
- Manuscript Accepted: 20 DEC 2012
- Manuscript Received: 5 OCT 2012
- “ADI–Agencia de Inovação.” IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Education and Science
- FCT, the Portuguese Foundation for Science and Technology
- ion torrent
The introduction of the benchtop massive parallel sequencers made it possible for the majority of clinical diagnostic laboratories to gain access to this fast evolving technology. In this study, using the Ion Torrent Personal Genome Machine, we present a strategy for the molecular diagnosis of hereditary breast and ovarian cancer and respective analytical validation. The methodology relies on a multiplex PCR amplification of the BRCA1 and BRCA2 genes combined with a variant prioritization pipeline, designed to minimize the number of false-positive calls without the introduction of false-negative results. A training set of samples was used to optimize the entire process, and a second set was used to validate and independently evaluate the performance of the workflow. Performing the study in a blind manner relative to the variants in the samples and using conventional Sanger sequencing as standard, the workflow resulted in a strategy with a maximum analytical sensitivity ≥98.6% with a confidence of 95% and a specificity of 96.9%. Importantly, no true variant was missed. This study presents a comprehensive massive parallel sequencing–Sanger sequencing based strategy, which results in a high analytical sensitivity assay that provides a time- and cost-effective strategy for the identification of mutations in the BRCA1 and BRCA2 genes.